Two Toronto startups are developing psilocybin-based medications that could expand treatment options for those in need.

Here's What A Fund Manager Says See Also: LSD Microdosing For Depression? This Clinical Study Reveals Promising Results ...

He became interested in microdosing after hearing that Swiss chemist Albert Hofmann, the first person to synthesize LSD, had done it. In 2010, a curious Fadiman launched an experiment that he ...

The analysis revealed a significant increase in REM sleep (p = 0.0037), time asleep (p = 0.0026), and total sleep (p = 0.0027 ...

But, for a moment, I asked her to hear me out. Microdosing involves taking small, sub-perceptible amounts of a psychedelic drug like LSD or psilocybin (the psychedelic agent in ‘magic mushrooms ...

The University of Virginia Health Toxicology Laboratory found psilocin (a psychoactive compound in magic mushrooms) in one product — but in hundreds of clinical studies, psilocin hasn’t caused these ...

In short, microdosing involves taking very small doses of psychedelic drugs, such as LSD (lysergic acid diethylamide) or psilocybin mushrooms, on a semi-regular schedule in order to experience ...

Psychedelic drugs had become more readily available to the public, and Witt—a contributor to publications including The New ...

With microdosing, users take fractional doses of what might ordinarily be considered a recreational substance like LSD, ecstasy, or magic mushrooms, attempting to stay below the hallucinogenic ...

The burgeoning psychedelic sector is attracting attention from investors as more companies have gone public, and research has increased rapidly due to greater mainstream and government acceptance ...